Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease [Phase 2]

View source ↗

Summary

Phase 2 study of arsenic trioxide in relapsed or refractory Hodgkin lymphoma; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Northwestern University | Conditions: Lymphoma | Phase 2 | Status: TERMINATED